Experimental study on the effect of silencing PRR13 on oxaliplatin resistance in colorectal cancer cells
10.3760/cma.j.cn115396-20200506-00130
- VernacularTitle:沉默 PRR13基因对结直肠癌细胞奥沙利铂耐药性影响的实验研究
- Author:
Xiaona ZHOU
1
;
Jin WANG
;
Lan JIN
;
Zhongtao ZHANG
Author Information
1. 首都医科大学附属北京友谊医院普外科 100050
- From:
International Journal of Surgery
2020;47(7):464-470,f4
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the effect of PRR13 expression and the sensitivity of colorectal cancer cells to oxaliplatin, as well as the effect of PRR13 expression on the apoptosis rate of colorectal cancer cells under the action of oxaliplatin. Methods:Two colorectal cancer cell lines(SW620, SW480) were screened from the colorectal cancer cell lines commonly used by ATCC. Lentiviral vectors were used for cell transfection to construct a PRR13-silent colorectal cancer cell model. MTT oxaliplatin drug sensitivity experiments were conducted and compared. In this study, a colorectal cell model stably transfected with shRNA lentivirus containing the silenced PRR13 sequence was defined as the silent group, and a colorectal cell model stably transfected with empty vector of lentivirus was defined as the control group. After silencing the PRR13, the colorectal cancer cells changed the IC 50 of oxaliplatin, and then used a double staining flow cytometry apoptosis experiment to compare the expression of PRR13 and the rate of apoptosis of colorectal cancer cells under the action of oxaliplatin relationship. The measurement data were expressed as mean±standard deviation ( Mean± SD), and the comparison between groups used independent sample t test. The count data were expressed as percentage (%), and the comparison between groups used chi-square test. Results:The IC 50 of the same cell model decreased significantly with time. At the same time point, the IC 50 of the silent group was significantly lower than that of the control group. In the same cell model with the same concentration, the apoptosis rate of the silent group was significantly higher than that of the control group (SW620 silent group 22.5% vs SW620 control group 11.35%, SW480 silent group 13.63% vs SW480 control group 4.59%), the ratio of viable cells was significantly lower than that of the control cell model (SW620 silent group 76.0% vs SW620 control group 87.2%, SW480 silent group 74.5% vs SW480 control group 89.3%). Conclusion:Silencing the PRR13 can reduce the sensitivity of cells to oxaliplatin and reduce the drug resistance of oxaliplatin and the effect of treatment is more significant.
